Global Cystic Fibrosis Therapeutics Market and Investment Analysis Report 2017-2022

The Global Cystic Fibrosis Therapeutics industry has reported a tremendous growth in the recent years, and is presenting ample opportunities to the industry players. With improving life expectancy and rising awareness, the global cystic fibrosis therapeutics market is poised to scale newer acmes. Also, there lies enormous opportunity for industry participants to tap the fast growing market, which would garner huge revenue on the back of rising strategic consolidations and commercialization of the new drugs targeting the CFTR gene or protein.

Browse the report: http://www.orbisresearch.com/reports/index/global-cystic-fibrosis-therapeutics-market-outlook-2022

The latest research by RNCOS titled, “Global Cystic Fibrosis Therapeutics Market Outlook 2022”, unfolds the market dynamics of the cystic fibrosis therapeutics market. According to this new research report, the market for cystic fibrosis therapeutics was valued at US$ 1.94 Billion in 2016.

The report showcases the segmentation of cystic fibrosis therapeutics market on the basis of the pharmacological class, mutation class, drug molecule type, and geographical penetration. It also provides an insight on the current market scenario, as well as forecasts of the aforementioned segments till 2022. The report provides an in-depth analysis of all the major segments, taking into account the major developments taking place at global level in the respective segments that will further boost the growth of cystic fibrosis therapeutics market.

Based on pharmacological class, the report broadly categorizes cystic fibrosis therapeutics market into Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Mucolytic agents, Pancreatic Enzymes products, Antibiotics, and Other therapies. CFTR modulators emerged as the major revenue earners of the industry, holding the largest share. This large share of the market is attributed to recent market approvals of Kalydeco (ivacaftor) and Orkambi (lumacaftor and ivacaftor) for the treatment of patients with CF and robust pipeline.

Request a free sample of the report: http://www.orbisresearch.com/contacts/request-sample/352746

Based on CF mutation class, the cystic fibrosis therapeutics market is further categorized into commercialized and non-commercialized mutation class specific therapies. CFTR mutation Class II accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Based on drug molecule type, the cystic fibrosis therapeutics market is further categorized into small molecule and biologic. The small molecule segment accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Additionally, the report covers the geographic analysis of the global cystic fibrosis therapeutics market by segmenting into three major geographic regions – North America, Europe, and Asia Pacific. North America is the largest market for cystic fibrosis. This high share is attributed to increasing awareness in the market, coupled with growing research initiatives. However, the European market is poised to witness the highest growth owing to increasing focus of players in this region.

Besides, the report covers the profiles of key players like Genentech, Inc. (A Member of the Roche Group), Novartis, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Gilead Sciences, Inc., Allergan plc, etc. with the key financials, providing a comprehensive outlook of global cystic fibrosis therapeutics industry. In addition, the report elucidates key developments of players related to cystic fibrosis industry. Overall, the report provides all the pre-requisite information for clients looking to venture in this industry, and facilitate them to formulate schemes while going for an investment/partnership in the industry.

List of Figures:
Figure 4-1: %age of CF individuals over the age of 18
Figure 4-2: Estimated Prevalence of Cystic Fibrosis per 100,000 Habitants, 2015-2016
Figure 4-3: Effect of novel therapies on life expectancy of cystic fibrosis patients
Figure 5-1: Global – Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 6-1: Global – Sales of Orkambi (Million US$), 2015 & 2016
Figure 6-2: Global – Sales of Kalydeco (Million US$), 2012-2016
Figure 6-3: Global – Sales of Cayston (Million US$), 2014-2016
Figure 6-4: Global – Sales of Pulmozyme (Million US$), 2012-2016
Figure 6-5: Global – Sales of TOBI (Million US$), 2014-2016
Figure 6-6: Global – Sales of Creon (Million US$), 2014-2016
Figure 6-7: Global – Sales of Zenpep (Million US$), 2014-2016
Figure 6-8: Global – Sales of Ventolin (Million US$), 2014-2016
Figure 6-9: Global – Sales of Bronchitol (Million US$), 2014-2016

List of Tables:
Table 4 -1: Global – Key Cystic Fibrosis Drugs and Patent Expiry Status
Table 12-1: Global – Cystic Fibrosis Products Pipeline Analysis
Table 14-1: Global – Major Cystic Fibrosis Drugs
Table 15-1: F. Hoffman La Roche Ltd. – Key Financials (Billion US$), 2014-2016
Table 15-2: Genentech, Inc. – Commercialized Cystic Fibrosis Product
Table 15-3: Genentech, Inc. – Cystic Fibrosis Drugs in Pipeline
Table 15-4: Novartis – Key Financials (Billion US$), 2014-2016
Table 15-5: Novartis – Commercialized Cystic Fibrosis Product
Table 15-6: Novartis – Cystic Fibrosis Drugs in Pipeline
Table 15-7: Vertex Pharmaceuticals Incorporated – Key Financials (Million US$), 2014-2016
Table 15-8: Vertex Pharmaceuticals Incorporated – Commercialized Cystic Fibrosis Product

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s